CRP and rheumatoid arthritis: As a means of predicting and monitoring drug treatment in rheumatoid arthritis, cytokines have been considered as potential biomarkers to use in parallel with CRP and ESR to monitor disease activity, but even these established acute phase-reactant levels can be discordant among RA patients with active disease [9].